Table 1.
Characteristic | Overall
|
DTC
|
p | |
---|---|---|---|---|
Yes
|
No
|
|||
n (%) | n (%) | n (%) | ||
Controls | 34 | 3 (9) | 31 (91) | |
All Pre-RP | 569 | 408 (72) | 161 (28) | <0.001 |
Pathologic stage | ||||
pT2 | 461 (81) | 331 (72) | 130 (28) | |
pT3-4, N0 | 72 (13) | 49 (68) | 23 (32) | |
pTany, N+ | 32 (6) | 25 (78) | 7 (22) | 0.57 |
Gleason grade | ||||
4–6 | 235 (41) | 181 (77) | 54 (23) | |
7 | 286 (50) | 194 (68) | 92 (32) | |
8–10 | 44 (8) | 30 (68) | 14 (32) | 0.06 |
PSA (ng/ml) | ||||
<4 | 110 (19) | 83 (75) | 27 (25) | |
4–10 | 360 (63) | 253 (70) | 107 (30) | |
10–20 | 79 (14) | 60 (76) | 19 (24) | |
>20 | 20 (4) | 12 (60) | 8 (40) | 0.37 |
Tumor volume (cc) | ||||
0.01–0.5 | 95 (17) | 72 (76) | 23 (24) | |
0.6–2.0 | 217 (38) | 161 (74) | 56 (26) | |
2.1–5.0 | 190 (33) | 123 (65) | 67 (35) | |
>5.0 | 63 (11) | 49 (78) | 14 (22) | 0.07 |
Abbreviations: DTC, disseminated tumor cells; PSA, prostate specific antigen